keyword
Keywords Cholangiocarcinoma AND unresec...

Cholangiocarcinoma AND unresectability

https://read.qxmd.com/read/38334150/advances-in-research-and-application-of-photodynamic-therapy-in-cholangiocarcinoma-review
#21
JOURNAL ARTICLE
Yufeng Li, Yuhang Li, Yinghui Song, Sulai Liu
Cholangiocarcinoma (CCA) is a disease characterized by insidious clinical manifestations and challenging to diagnose. Patients are usually diagnosed at an advanced stage and miss the opportunity for radical surgery. Therefore, effective palliative therapy is the main treatment approach for unresectable CCA. Current common palliative treatments include biliary drainage, chemotherapy, radiotherapy, targeted therapy and immunotherapy. However, these treatments only offer limited improvement in quality of life and survival...
March 2024: Oncology Reports
https://read.qxmd.com/read/38329716/safety-profile-and-adverse-event-management-for-futibatinib-an-irreversible-fgfr1-4-inhibitor-pooled-safety-analysis-of-469-patients
#22
JOURNAL ARTICLE
Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do-Youn Oh, John A Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
PURPOSE: Futibatinib, a covalently-binding inhibitor of fibroblast growth factor receptor (FGFR)1-4 gained approval for the treatment of refractory, advanced intrahepatic cholangiocarcinoma (iCCA) harboring an FGFR2 fusion/other rearrangement. An integrated analysis was performed to evaluate safety and provide guidance on management of futibatinib-associated adverse events (AEs) in patients with unresectable/metastatic tumors, including iCCA. PATIENTS AND METHODS: Data from three global phase 1 or 2 studies of futibatinib (NCT02052778; JapicCTI-142552) were pooled...
February 8, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38326663/robotic-alpps-for-primary-and-metastatic-liver-tumours-short-term-outcomes-versus-open-approach
#23
JOURNAL ARTICLE
Paolo Magistri, Cristiano Guidetti, Barbara Catellani, Daniela Caracciolo, Roberta Odorizzi, Samuele Frassoni, Vincenzo Bagnardi, Gian Piero Guerrini, Stefano Di Sandro, Fabrizio Di Benedetto
Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) is one of the strategies available for patients initially unresectable. High risk of peri-operative morbidity and mortality limited its application and diffusion. We aimed to analyse short-term outcomes of robotic ALPPS versus open approach, to assess safety and reproducibility of this technique. A retrospective analysis of prospectively maintained databases at University of Modena and Reggio Emilia on patients that underwent ALPPS between January 2015 and September 2022 was conducted...
February 7, 2024: Updates in Surgery
https://read.qxmd.com/read/38323680/advancing-complex-hepato-pancreato-biliary-surgery-in-uganda-challenges-and-outcomes
#24
JOURNAL ARTICLE
Okello Michael, Dave Darshit, Kiconco Mary, Umar Mutekoba, Mugabi Timothy, Baseka Xavier Francis, Kakaire Denis, Kyomugisha Edward, Okuku Fred Machyo, Ddungu Henry, Buwembo William, Ocama Ponsiano
INTRODUCTION: Uganda has until recently mostly referred patients for complex hepato-pancreato-biliary (HPB) surgery abroad due to lack of local expertize. We report indications and a spectrum of surgeries performed in the first 4 years following the establishment of a routine HPB service at Lubaga Hospital (LH), Kampala, Uganda. We also detailed the challenges encountered in setting up this service. METHODS: Demographic, clinical parameters, surgery indications, procedures performed, and outcomes of consecutive patients that underwent HPB surgeries at LH from December 2018 to October 2022 were analyzed...
February 7, 2024: World Journal of Surgery
https://read.qxmd.com/read/38322206/molecular-pathology-for-cholangiocarcinoma-a-review-of-actionable-genetic-targets-and-their-relevance-to-adjuvant-neoadjuvant-therapy-staging-follow-up-and-determination-of-minimal-residual-disease
#25
REVIEW
Emilie A K Warren, Shishir K Maithel
Cholangiocarcinoma (CCA) represents a group of epithelial cell tumors classified based on their anatomic location along the biliary tree. This rare malignancy is often diagnosed at an advanced stage and deemed unresectable. Even for those patients who are surgical candidates, recurrence rates are high and survival rates low. The mainstay of therapy for advanced CCA remains cisplatin plus gemcitabine, with a median overall survival (mOS) under 12 months, although the TOPAZ-1 trial showed a survival benefit with the addition of programmed cell death ligand 1 (PD-L1) blockade...
February 1, 2024: Hepatobiliary Surgery and Nutrition
https://read.qxmd.com/read/38321223/factors-impacting-survival-after-transarterial-radioembolization-in-patients-with-unresectable-intrahepatic-cholangiocarcinoma-a-combined-analysis-of-the-prospective-cirt-studies
#26
JOURNAL ARTICLE
Peter Reimer, Valérie Vilgrain, Dirk Arnold, Tugsan Balli, Rita Golfieri, Romaric Loffroy, Cristina Mosconi, Maxime Ronot, Christian Sengel, Niklaus Schaefer, Geert Maleux, Graham Munneke, Bora Peynircioglu, Bruno Sangro, Nathalie Kaufmann, Maria Urdaniz, Helena Pereira, Niels de Jong, Thomas Helmberger
PURPOSE: Transarterial radioembolization (TARE) with Yttrium-90 resin microspheres is a treatment option for patients with intrahepatic cholangiocarcinoma (ICC). However, optimising the timing of TARE in relation to systemic therapies and patient selection remains challenging. We report here on the effectiveness, safety, and prognostic factors associated with TARE for ICC in a combined analysis of the prospective observational CIRT studies (NCT02305459 and NCT03256994). METHODS: A combined analysis of 174 unresectable ICC patients enrolled between 2015 and 2020 was performed...
February 6, 2024: Cardiovascular and Interventional Radiology
https://read.qxmd.com/read/38319509/skeletal-muscle-status-and-survival-among-patients-with-advanced-biliary-tract-cancer
#27
JOURNAL ARTICLE
Shinya Takaoka, Tsuyoshi Hamada, Naminatsu Takahara, Kei Saito, Go Endo, Ryunosuke Hakuta, Kota Ishida, Kazunaga Ishigaki, Sachiko Kanai, Kohei Kurihara, Hiroki Oyama, Tomotaka Saito, Tatsuya Sato, Tatsunori Suzuki, Yukari Suzuki, Shuichi Tange, Yurie Tokito, Ryosuke Tateishi, Yousuke Nakai, Mitsuhiro Fujishiro
BACKGROUND: Studies have demonstrated a prognostic role of sarcopenia (i.e., loss of skeletal muscle volume and functionality) in patients with various cancer types. In patients with biliary tract cancer, the quantity and quality of skeletal muscles and their serial changes have not been fully investigated in relation to survival outcomes. METHODS: We identified 386 patients with unresectable or recurrent biliary tract cancer and calculated skeletal muscle index (SMI) and skeletal muscle density (SMD) to estimate muscular quantity and quality, respectively, based on computed tomography images...
February 6, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38310060/liver-transplantation-as-an-alternative-for-the-treatment-of-perihilar-cholangiocarcinoma-a-critical-review
#28
REVIEW
Wellington Andraus, Francisco Tustumi, Alexandre Chagas Santana, Rafael Soares Nunes Pinheiro, Daniel Reis Waisberg, Liliana Ducatti Lopes, Rubens Macedo Arantes, Vinicius Rocha Santos, Rodrigo Bronze de Martino, Luiz Augusto Carneiro D'Albuquerque
BACKGROUND: Perihilar cholangiocarcinoma (phCCC) is a dismal malignancy. There is no consensus regarding the best treatment for patients with unresectable phCCC. The present review aimed to gather the current pieces of evidence for liver transplantation and liver resection as a treatment for phCCC and to build better guidance for clinical practice. DATA SOURCES: The search was conducted in PubMed, Embase, Cochrane, and LILACS. The related references were searched manually...
January 20, 2024: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://read.qxmd.com/read/38303305/-a-case-of-intrahepatic-cholangiocarcinoma-in-contact-with-the-gastroduodenal-anastomosis-in-which-proton-beam-therapy-was-performed-after-placement-of-an-absorbable-spacer
#29
JOURNAL ARTICLE
Yuriko Uehara, Tomoya Shamoto, Hiroyuki Ogino, Yuri Yokoi, Shohei Hayashi, Eri Tsuji, Nanako Ando, Tomotaka Okubo, Masayasu Hara, Akira Mitsui, Yoichi Matsuo, Masahiro Kimura, Shuji Takiguchi
Chemotherapy is the standard therapy for unresectable intrahepatic cholangiocarcinoma(ICC), but chemotherapy is not efficacious. Proton beam therapy(PBT)has been covered by Japanese health insurance for ICC since 2022, and the number of cases is expected to increase. In some cases, irradiation is difficult due to the close proximity of the gastrointestinal tract to the tumor. We report our management of a patient with ICC close to the gastrointestinal tract. The patient was a 69-year- old woman with a history of distal gastrectomy and Billroth-Ⅰ reconstruction for gastric cancer...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38301963/enteroblastic-cholangiocarcinoma-an-uncommon-underrecognized-subtype-of-bile-duct-cancer
#30
JOURNAL ARTICLE
Jihyun Chun, Michelle Moore, Paul Kelly, Maki Kanzawa, Tomoo Itoh, Seung-Mo Hong, Yoh Zen
Enteroblastic carcinoma is clinically characterized by an elevated serum level of alpha-fetoprotein (AFP) and is histologically characterized by cancer cells with a clear cytoplasm and 'blastic' coarse chromatin. It sometimes has an element of hepatoid carcinoma; therefore, these two neoplasms are often regarded as sister entities. Although hepatoid carcinoma in the biliary tree has been reported, enteroblastic cholangiocarcinoma is extremely uncommon. In the present study, four cases of enteroblastic cholangiocarcinoma were examined...
January 30, 2024: Human Pathology
https://read.qxmd.com/read/38273745/exploring-molecular-mechanisms-in-the-second-line-treatment-of-biliary-tract-malignant-tumors
#31
REVIEW
QianLin Liu, PengFei Zhang, Qiu Li
Biliary tract malignant tumors account for about 3% of gastrointestinal malignancies. Based on anatomical location, biliary tract malignant tumors can be divided into gallbladder carcinoma, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma, and distal cholangiocarcinoma. Surgical treatment is the main treatment for early-stage biliary malignant tumors, the insidious nature of the disease often leads to late diagnoses, causing many patients missing the window for surgical intervention. Gemcitabine combined with cisplatin serves as a first-line treatment for patients with advanced or unresectable lesions, however, a definitive standard for second-line treatment has not yet been established...
January 2024: Discovery Medicine
https://read.qxmd.com/read/38258823/liver-transplantation-for-intrahepatic-cholangiocarcinoma-who-when-and-how
#32
JOURNAL ARTICLE
Pablo Achurra, Eduardo Fernandes, Grainne O'Kane, Robert Grant, Mark Cattral, Gonzalo Sapisochin
PURPOSE OF REVIEW: Using transplant oncology principles, selected patients with intrahepatic cholangiocarcinoma (iCCA) may achieve long-term survival after liver transplantation. Strategies for identifying and managing these patients are discussed in this review. RECENT FINDINGS: Unlike initial reports, several modern series have reported positive outcomes after liver transplantation for iCCA. The main challenges are in identifying the appropriate candidates and graft scarcity...
January 24, 2024: Current Opinion in Organ Transplantation
https://read.qxmd.com/read/38240385/laparoscopic-ultrasonography-along-with-staging-laparoscopy-as-a-tool-for-staging-in-patients-with-hepatopancreaticobiliary-malignancy-a-prospective-cohort-study-from-a-tertiary-care-centre
#33
JOURNAL ARTICLE
Sanjeet Kumar Rai, Shakti Swaroop Sarangi, Krishna Asuri, Om Prakash Prajapati, Ankur Goyal, Virinder Kumar Bansal
INTRODUCTION: Staging laparoscopy (SL) plays an important role in avoiding unnecessary non-therapeutic laparotomy in radiologically resectable hepatopancreaticobiliary (HPB) malignancy patients. The limitation of SL is to detect deep-seated malignancy. The addition of laparoscopic ultrasonography for identifying metastatic lesions or locally unresectable disease improves the diagnostic yield of SL. PATIENTS AND METHODS: This prospective, observational study was conducted in a single unit of the tertiary care centre between 2017 and 2019...
January 1, 2024: Journal of Minimal Access Surgery
https://read.qxmd.com/read/38223418/any-role-for-transarterial-radioembolization-in-unresectable-intrahepatic-cholangiocarcinoma-in-the-era-of-advanced-systemic-therapies
#34
REVIEW
Alessandra Elvevi, Alice Laffusa, Federica Elisei, Sabrina Morzenti, Luca Guerra, Antonio Rovere, Pietro Invernizzi, Sara Massironi
Intrahepatic cholangiocarcinoma (iCCA) is recognized as the second most frequently diagnosed liver malignancy, following closely after hepatocellular carcinoma. Its incidence has seen a global upsurge in the past several years. Unfortunately, due to the lack of well-defined risk factors and limited diagnostic tools, iCCA is often diagnosed at an advanced stage, resulting in a poor prognosis. While surgery is the only potentially curative option, it is rarely feasible. Currently, there are ongoing investigations into various treatment approaches for unresectable iCCA, including conventional chemotherapies, targeted therapies, immunotherapies, and locoregional treatments...
December 27, 2023: World Journal of Hepatology
https://read.qxmd.com/read/38223257/a-phase-ii-study-to-evaluate-the-safety-and-efficacy-of-anlotinib-combined-with-toripalimab-for-advanced-biliary-tract-cancer
#35
JOURNAL ARTICLE
Mingzhen Zhou, Yuncheng Jin, Sihui Zhu, Chen Xu, Lin Li, Baorui Liu, Jie Shen
OBJECTIVES: To assess the safety and efficacy of anlotinib (a multi-targeted tyrosine kinase inhibitor) combined with toripalimab (a PD-1 monoclonal antibody) in the treatment of unresectable biliary tract cancer (BTC). METHODS: In this prospective, single-arm, single-centre exploratory clinical study, patients with locally progressed or metastatic BTC were included. Patients were treated with anlotinib (12 mg, PO, QD, for 2 weeks and then stopped for a week, 21 days for a cycle) and toripalimab (240 mg, IV, Q3W)...
2024: Clinical & Translational Immunology
https://read.qxmd.com/read/38206555/pemigatinib-a-review-in-advanced-cholangiocarcinoma
#36
REVIEW
James E Frampton
Pemigatinib (Pemazyre® ), a selective, potent, reversible, oral inhibitor of fibroblast growth factor receptor (FGFR) 1-3, has received conditional (in the EU) or accelerated (in the USA) approval for the treatment of adults with previously treated, unresectable locally-advanced or metastatic cholangiocarcinoma (CCA) with an FGFR2 gene fusion or rearrangement. Over the course of a single-arm, phase 2 study (FIGHT-202), just over a third of patients with pretreated, advanced CCA [almost exclusively intrahepatic CCA (iCCA)] harbouring an FGFR2 fusion or rearrangement who received pemigatinib once daily (2 weeks on, 1 week off) had an objective response; nearly half had stable disease...
January 2024: Targeted Oncology
https://read.qxmd.com/read/38188927/intraductal-radiofrequency-ablation-plus-biliary-stent-versus-stent-alone-for-malignant-biliary-obstruction-a-systematic-review-and-meta-analysis
#37
REVIEW
Matheus de Oliveira Veras, Diogo Turiani Hourneaux de Moura, Thomas R McCarty, Guilherme Henrique Peixoto de Oliveira, Rômulo Sérgio Araújo Gomes, Davi Lucena Landim, Felipe Giacobo Nunes, Tomazo Antônio Prince Franzini, Marcos Eduardo Lera Dos Santos, Wanderley Marques Bernardo, Eduardo Guimarães Hourneaux de Moura
Background and study aims Recurrent biliary stent occlusion and tumor ingrowth remain a major concern among patients with malignant biliary obstruction (MBO) with significant impact on patient morbidity and survival. Intraductal radiofrequency ablation (RFA) has emerged as a promising treatment that seeks to extend stent patency. This study aimed to evaluate the impact of RFA on overall survival (OS) and stent patency among patients with unresectable MBO. Methods A comprehensive search of electronic databases was performed for randomized controlled trials (RCTs) comparing RFA plus biliary stent (RFA+S) versus biliary stent alone (S-alone)...
January 2024: Endoscopy International Open
https://read.qxmd.com/read/38186240/combined-high-dose-radiotherapy-with-sequential-gemcitabine-cisplatin-based-chemotherapy-increase-the-resectability-and-survival-in-locally-advanced-unresectable-intrahepatic-cholangiocarcinoma-a-multi-institutional-cohort-study
#38
JOURNAL ARTICLE
Jung Ho Im, Jeong Il Yu, Tae Hyun Kim, Tae Gyu Kim, Jun Won Kim, Jinsil Seong
PURPOSE: The locally advanced unresectable intrahepatic cholangiocarcinoma (ICC) has detrimental oncological outcomes. In this study, we aimed to investigate the efficacy of radiotherapy in patients with locally advanced unresectable ICC. MATERIALS AND METHODS: Between 2001 and 2021, 116 patients were identified through medical record who underwent radiotherapy for locally advanced unresectable ICC. The resectability of ICC is determined by the multidisciplinary team at each institution...
January 2, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38142182/single-center-experience-using-stereotactic-body-radiation-therapy-sbrt-on-orthotopic-liver-transplant-protocol-for-unresectable-cholangiocarcinoma
#39
JOURNAL ARTICLE
Trudy C Wu, Jie Deng, Fang-I Chu, Saeed Sadeghi, Richard Finn, Vatche G Agopian, Percy Lee, Ann C Raldow
PURPOSE: To evaluate tolerability, pathologic response, and disease outcomes utilizing pre-operative stereotactic body radiation therapy (SBRT) followed by consolidation chemotherapy (CHT) prior to orthotopic liver transplant (OLT) in unresectable cholangiocarcinoma (CCA). METHODS: This was a retrospective chart review of patients treated on OLT protocol at a single tertiary center from 2012 to 2019. Patients received pre-operative SBRT (40-50 Gy in 5 fractions) followed by CHT until progression or OLT...
December 10, 2023: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://read.qxmd.com/read/38108100/molecular-targeted-and-systemic-therapy-for-intrahepatic-cholangiocarcinoma-a-multi-disciplinary-approach
#40
REVIEW
Katiuscha Merath, Ankur Tiwari, Alexander A Parikh, Timothy M Pawlik
Most patients with intrahepatic cholangiocarcinoma (ICC) are diagnosed with advanced disease. For individuals with resectable tumors, R0 resection with lymphadenectomy is the best potentially curative-intent treatment. After resection, adjuvant therapy with capecitabine is the current standard of care. For patients with unresectable or distant metastatic disease, doublet chemotherapy with gemcitabine and cisplatin is the most utilized first-line regimen, but recent studies using triplet regimens and even the addition of immunotherapy have begun to shift the paradigm of systemic therapy...
December 18, 2023: Future Oncology
keyword
keyword
158466
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.